Prithviraj Bose, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the promise of momelotinib in the treatment of myelofibrosis (MF), highlighting the anemia benefit observed in patients receiving this agent. Dr Bose also discusses clinical trials which have evaluated the efficacy of momelotinib, including the SIMPLIFY-1 and SIMPLIFY-2 trials (NCT01969838, NCT02101268) and the MOMENTUM trial (NCT04173494), and further comments on the value of adding momelotinib to the MF treatment armamentarium. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
